ArticleEuropean heart journal. Imaging methods and practice2026
Visual standardized quantification of late gadolinium enhancement, a contour-less method for late gadolinium enhancement quantification.
Article in European heart journal. Imaging methods and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Late gadolinium enhancement (LGE) quantification by cardiovascular magnetic resonance is central to risk stratification in hypertrophic cardiomyopathy (HCM). Conventional techniques require contour tracing and region of interest (ROI) placement, which may reduce reproducibility and increase analysis time. We developed a novel visual approach, the visual standardized quantification (VISTAQ) of LGE, that does not require myocardial contouring, arbitrary ROI positioning, or dedicated post-processing software. Methods and results: LGE images from 400 patients (100 prior myocardial infarction, 250 HCM, and 50 other non-ischaemic heart diseases) were analysed. Reproducibility was assessed using the intra-class correlation coefficients (ICC) and Bland-Altman analysis. VISTAQ was compared with conventional methods [mean+2SD, +5SD, +6SD, full-width-at-half-maximum (FWHM), visual thresholding]. Prognostic performance was evaluated in 250 HCM patients. VISTAQ demonstrated excellent intra- and inter-observer reproducibility (ICC up to 0.98 and 0.97, respectively), consistent across disease subtypes. VISTAQ showed similar ICC to FWHM but significantly lower net and absolute inter-observer differences (median absolute difference: 1.3%). Mean+2SD markedly overestimated LGE, whereas mean+6SD slightly underestimated LGE compared with VISTAQ, mean+5SD, FWHM, and visual thresholding. Analysis time was shorter with VISTAQ (median 105 vs. 375 s, Conclusion: VISTAQ provides highly reproducible, time-efficient LGE quantification without dedicated software and demonstrates non-inferior prognostic discrimination in HCM compared with conventional threshold-based techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.